Key result
Cardiac amyloidosis carries a ~17% prevalence of intracardiac thrombus despite anticoagulation.
Meta-Analysis (n=631)
Intracardiac and left atrial appendage thrombi are common in patients with cardiac amyloidosis (16.7% overall prevalence) and frequently occur despite documented oral anticoagulation, supporting a lower threshold for pre-procedural imaging-based thrombus exclusion.
Answers are grounded in this paper and cite their sources.
May warrant pre-procedural imaging despite anticoagulation; challenges assumptions on thrombus prevention in cardiac amyloidosis.
Background: Cardiac amyloidosis (CA) is a high-risk thromboembolic substrate driven by atrial arrhythmias and amyloid-related atrial mechanical dysfunction. In practice, anticoagulation status guides the need for thrombus-exclusion imaging before cardioversion or other rhythm-control strategies. However, intracardiac and left atrial appendage (LAA) thrombi have been reported despite oral anticoagulation, raising concern that anticoagulation alone may be insufficient to exclude thrombus risk in CA. Objective: To evaluate the prevalence of intracardiac and LAA thrombus in adults with CA and characterize thrombus detected despite oral anticoagulation. Methods: We performed a PRISMA-guided systematic review and meta-analysis searching PubMed, Scopus, and Web of Science for adult studies of confirmed CA reporting imaging- or pathology-confirmed intracardiac, left atrial, or LAA thrombus with extractable event counts and denominators. Random-effects meta-analysis of proportions was performed for imaging-based studies. Pre-cardioversion cohorts were analyzed as a prespecified subgroup. Thrombus despite anticoagulation and autopsy/pathology cohorts were summarized separately. Study quality was evaluated using the Joanna Briggs Institute checklist. Results: Five imaging-based studies including 631 CA patients assessed for thrombus were included. Intracardiac/LAA thrombus was identified in 92 patients, with a pooled prevalence of 16.7% (95% CI, 9.8%-27.2%; I 2 =89.9%). In pre-cardioversion cohorts, pooled prevalence was 19.9% (95% CI, 13.6%-28.2%; I 2 =43.6%). Sensitivity analysis excluding a procedure-level cohort yielded a similar pooled prevalence of 16.1%. In studies with extractable anticoagulated denominators, thrombus was detected in 12.8% of anticoagulated patients undergoing assessment. Among studies reporting anticoagulation status of thrombus cases, at least 49.1% occurred despite documented anticoagulation. Imaging-based studies were generally at low to moderate risk of bias, mainly due to selective thrombus assessment and clinical-setting heterogeneity. Conclusion: Intracardiac and LAA thrombi are clinically common in CA, occurring in anticoagulated patients and pre-cardioversion settings where a missed thrombus may alter management. These findings support amyloid atrial myopathy as a distinct thrombotic substrate not reliably mitigated by conventional anticoagulation strategies. A lower threshold for imaging-based thrombus exclusion before cardioversion/rhythm-control procedures may be warranted in selected CA patients, even when anticoagulation appears adequate. Prospective studies are needed to define optimal thrombus-exclusion strategies, identify predictors of thrombus despite anticoagulation, and test whether CA-specific anticoagulation or rhythm-control pathways reduce thromboembolic events.
No takes yet. Share an insight, caveat, or question.
Alhaddadin et al. (2026) conducted a meta-analysis in Cardiac amyloidosis (n=631). Cardiac amyloidosis (including patients on oral anticoagulation) was evaluated on Prevalence of imaging-confirmed intracardiac or left atrial appendage thrombus (Pooled prevalence 16.7%, 95% CI 9.8%-27.2%). Cardiac amyloidosis carried a 16.7% pooled prevalence of intracardiac/LAA thrombus, with 12.8% of anticoagulated patients having thrombus.
Synapse has enriched 10 related papers. Consider them for comparative context: